UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 131

of 'Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia'

131
TI
Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission.
AU
Ali R, OzkalemkaşF, Ozçelik T, Ozkocaman V, Ozan U, Kimya Y, Köksal N, Gülten T, Yakut T, Tunali A
SO
Leuk Res. 2005;29(8):971. Epub 2005 Feb 16.
 
Because of the teratogenicity data in rats, it is recommended that women treated with imatinib should be aware of the potential teratogenicity of imatinib and effective contraception should be used during imatinib therapy to prevent pregnancy. We describe successful pregnancy and delivery, without any congenital anomaly, in a patient with CML under treatment of imatinib. The fetus had been exposed to imatinib for 8 weeks. The patient remained off treatment during gestation and cytogenetic relapse of CML (5 months after discontinuation of imatinib therapy) developed at seventh month of gestation.
AD
Division of Hematology, Department of Internal Medicine, Uludag University School of Medicine, Bursa, Turkey. ridvanali@uludag.edu.tr
PMID